Početna › Multipli mijelom › Florida
Kliničke studije za Multipli mijelom u državi Florida
55 studija za Multipli mijelom traži sudionike na lokacijama u državi Florida.
Gradovi u državi Florida
- Miami21 studija
- Jacksonville18 studija
- Tampa15 studija
- Kendall6 studija
- Deerfield Beach5 studija
- Hollywood5 studija
- Plantation4 studija
- Coral Springs4 studija
- Pembroke Pines3 studija
- Fort Lauderdale3 studija
Službeni tekst studije (engleski)
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 102, St. Petersburg
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT07582432Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
- Mayo Clinic in Florida, Jacksonville
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06630104The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
- Mayo Clinic in Florida, Jacksonville
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07285044A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- Moffitt Cancer Center /ID# 279068, Tampa
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07409246A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Tampa
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07391657A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Miami, Miami
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT04973605A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Jacksonville, Jacksonville
- Memorial Cancer Institute, Pembroke Pines
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07518186Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- Comprehensive Hematology Oncology, St. Petersburg
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07609940A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Florida Cancer Specialists & Research Institute, Fort Myers
- Mayo Clinic Jacksonville, Jacksonville
- Moffit Cancer center, Tampa
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07258511A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Memorial Healthcare System, Hollywood
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT04634552A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Memorial Healthcare System, Hollywood
- AdventHealth Medical Group Blood & Marrow Transplant at Orlando, Orlando
- Cleveland Clinic Florida, Weston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05552222A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Jupiter Medical Center/Anderson Family Cancer Institute, Jupiter
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05623020A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Moffitt Cancer Center, Tampa
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05201781A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Cancer Specialists of North Florida, Jacksonville
- D&H National Research Center, Margate
- Ocala Oncology Center, Ocala
- i još 2
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT07477587TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Miami/Sylvester Cancer Institute - Aventura, Aventura
- University of Miami/Sylvester Cancer Institute - Lennar, Coral Gables
- University of Miami/Sylvester Cancer Institute - Deerfield Beach, Deerfield Beach
- i još 8
U tijeku regrutacijaFaza 2
Od 12 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT02693535Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Mayo Clinic in Florida, Jacksonville
- Moffitt Cancer Center, Tampa
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT06465316ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
- University of Miami, Miami
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT06997081Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- SSAK Partners, Coral Springs
- Mayo Clinic - Jacksonville, Jacksonville
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT07648264A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Baptist MD Anderson Cancer Center, Jacksonville
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic in Florida, Jacksonville
- Miami Cancer Institute at Baptist Health, Inc., Miami
- Moffitt Cancer Center, Tampa
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT06297226Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Florida, Jacksonville
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT06375044A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Moffitt Cancer Center, Tampa
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT07075185A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Tampa
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 27. kol 2026. · NCT07681596A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Fort Myers
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT07227311MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center, Coral Gables
- University of Miami Hospital and Clinics - Deerfield Beach, Deerfield Beach
- Sylvester Comprehensive Cancer Center- Doral, Doral
- i još 12
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 24. kol 2026. · NCT06152575A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Sylvester Comprehensive Cancer Center - Aventura, Aventura
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center, Coral Gables
- Sylvester Comprehensive Cancer Center - Coral Springs, Coral Springs
- i još 6
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 24. kol 2026. · NCT05020236A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Pembroke Pines
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT05714839Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Holy Cross Hospital, Fort Lauderdale
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT04566328IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
- University of Miami, Miami
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT06376526A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Mayo Clinic Hospital - Florida, Jacksonville
- University of Miami Don Soffer Clinical Research Center, Miami
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Jacksonville
- Research Site, Miami
- Research Site, Tampa
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 17. kol 2026. · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Coral Gables
- Research Site, Tampa
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. kol 2026. · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- University of Florida, Gainesville
- University of Miami, Miami
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 12. kol 2026. · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Mayo Clinic - Florida, Jacksonville
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 6. kol 2026. · NCT07284758A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Moffitt Cancer Center /ID# 272628, Tampa
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 21. srp 2026. · NCT06892522A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Mayo Clinic in Florida, Jacksonville
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 16. srp 2026. · NCT06121843Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
- Mayo Clinic in Florida, Jacksonville
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 14. srp 2026. · NCT05847569Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center, Coral Gables
- University of Miami Hospital and Clinics Deerfield Beach, Deerfield Beach
- Sylvester Comprehensive Cancer Center, Miami
- i još 2
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 1. srp 2026. · NCT06057402Integrated Cancer Repository for Cancer Research
- Florida Hospital Memorial Medical Center, Daytona Beach
- Florida Hospital DeLand, DeLand
- Florida Hospital FISH, Orange City
- i još 2
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 19 do 110 godina · Oba spola · Ažurirano 29. lip 2026. · NCT02012699Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Holy Cross Hospital, Fort Lauderdale
- Mayo Clinic in Florida, Jacksonville
- Jupiter Medical Center, Jupiter
U tijeku regrutacijaFaza 3
Sve dobne skupine · Oba spola · Ažurirano 10. lip 2026. · NCT05561387Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.